Expands AI-Ready Infrastructure in Asia Pacific Rendering of Digital Realty’s NRT14 data center in the Greater Tokyo area SINGAPORE, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Digital Realty (NYSE: DLR), the largest global provider of cloud- and carrier-neutral data center, colocation, and interconnection solutions, today announced that its upcoming NRT14 data center in the Greater Tokyo area will be one of the first facilities in Japan to achieve the DGX-Ready Data Center certification. The milestone reinforces D ...

Core Viewpoint - Eisai Co., Ltd. and Biogen Inc. announced that the Biologics License Application for the subcutaneous formulation of LEQEMBI has been designated for Priority Review by the National Medical Products Administration of China, which could significantly enhance patient access to treatment [1][2]. Group 1: Product Development and Approval - The subcutaneous formulation (SC-AI) of LEQEMBI allows for a once-weekly home administration, contrasting with the current intravenous method that requires hospital visits every two weeks [3]. - The injection time for each autoinjector is approximately 15 seconds, which could streamline the treatment process and reduce healthcare resource utilization [3]. - Eisai estimates that there were 17 million patients with mild cognitive impairment or mild dementia due to Alzheimer's disease in China in 2024, a number expected to rise with the aging population [4]. Group 2: Market Access and Insurance - LEQEMBI was launched in China in June 2024 and has been included in the "Commercial Insurance Innovative Drug List," effective January 2026, which supports access to innovative medicines [5]. - Commercial insurance companies are expected to develop insurance products covering LEQEMBI based on this new list [5]. Group 3: Collaboration and Regulatory Strategy - Eisai leads the global development and regulatory submissions for LEQEMBI, with both Eisai and Biogen co-commercializing and co-promoting the product [6][11]. - The U.S. FDA approved the Biologics License Application for subcutaneous maintenance dosing of LEQEMBI in August 2025, with a supplemental application for initiation treatment accepted in January 2026 [8]. Group 4: Scientific Background - Lecanemab is a humanized monoclonal antibody targeting aggregated forms of amyloid-beta, which is believed to play a significant role in cognitive decline associated with Alzheimer's disease [8][10]. - The reduction of protofibrils may prevent the progression of Alzheimer's disease by mitigating neuronal damage and cognitive dysfunction [10]. Group 5: Company Overview - Eisai's corporate concept focuses on patient-centric healthcare, aiming to address unmet medical needs, particularly in neurology and oncology [13]. - Biogen, founded in 1978, is a leading biotechnology company that emphasizes innovative science to transform patient lives and create shareholder value [16].

Columbus, OH, Feb. 08, 2026 (GLOBE NEWSWIRE) -- Grimes Financial Group, a fiduciary investment advisory firm based in Columbus, Ohio, continues to strengthen its comprehensive financial planning framework through The Retirement BlueprintTM to address the growing gap between standalone investing and fully coordinated retirement planning. The Retirement BlueprintTM The Retirement Blueprint is a structured approach that aligns retirement income strategy, investment management, tax efficiency, risk management, ...

Core Insights - Fangzhou Inc. has been awarded the "AI-Powered Future Award" by Tencent Health, highlighting its leadership in AI-driven chronic disease services and digital healthcare transformation [1][5]. Company Overview - Fangzhou Inc. is recognized as a leading "AI-enabled chronic care" platform in China, focusing on technology as a core growth driver [3]. - As of June 30, 2025, the company serves 52.8 million registered users and 229,000 physicians, specializing in tailored medical care and AI-enabled precision medicine solutions [10]. Strategic Developments - In 2025, Fangzhou upgraded its H2H (Hospital-to-Home) model to an "AI + H2H" smart healthcare ecosystem, emphasizing long-term doctor-patient relationships as a key differentiator in chronic disease management [3]. - The company has expanded its MaaS (Medicine as a Service) framework, integrating patient trust with service delivery capabilities to create scalable chronic disease management solutions [4]. Collaboration and Technology - The partnership with Tencent Health has been crucial, combining Fangzhou's domain knowledge with Tencent's cloud computing and AI infrastructure to establish a replicable model for intelligent chronic care services [6]. Performance Metrics - Fangzhou's AI-driven model has improved healthcare delivery by overcoming traditional constraints, leading to increased user engagement and platform activity [7]. - The company has issued a positive profit alert, forecasting 2025 revenue between RMB 3.5 billion and RMB 3.55 billion, reflecting approximately 30% year-on-year growth [8]. Future Outlook - Fangzhou plans to strengthen its MaaS system, enhance AI integration in chronic disease services, and expand access to technology-enabled care, reinforcing its role in China's healthcare digitization [9].

Core Insights - Fangzhou Inc. has been awarded the "AI-Powered Future Award" by Tencent Health, highlighting its leadership in AI-driven chronic disease services and digital healthcare transformation [1][5]. Company Overview - Fangzhou is recognized as one of China's leading platforms for AI-enabled chronic care, focusing on technology as a primary growth driver [3]. - As of June 30, 2025, the company serves 52.8 million registered users and 229,000 physicians, specializing in tailored medical care and AI-enabled precision medicine solutions [10]. Strategic Developments - In 2025, Fangzhou upgraded its Hospital-to-Home (H2H) model to an "AI + H2H" smart healthcare ecosystem, emphasizing long-term doctor-patient relationships as a key differentiator in chronic disease management [3]. - The company has expanded its Medicine as a Service (MaaS) framework, integrating patient trust with service delivery capabilities to create scalable chronic disease management solutions [4]. Collaboration and Technology - The partnership with Tencent Health has been crucial, combining Fangzhou's domain knowledge with Tencent's cloud computing and AI infrastructure to establish a replicable model for intelligent chronic care services [6]. Performance Metrics - Fangzhou's AI-driven model has improved healthcare delivery by overcoming traditional constraints, leading to increased user engagement and platform activity [7]. - The company has issued a positive profit alert, forecasting 2025 revenue between RMB 3.5 billion and RMB 3.55 billion, indicating approximately 30% year-on-year growth [8]. Future Outlook - Fangzhou plans to further strengthen its MaaS system, enhance AI integration in chronic disease services, and expand access to technology-enabled care, solidifying its role in China's healthcare digitization [9].

Ellicott City, MD, Feb. 08, 2026 (GLOBE NEWSWIRE) -- Many Maryland business owners are seeing revenue rise while feeling increasingly constrained by cash. To address the disconnect, Sustain CFO, a fractional CFO in Maryland, has developed a financial resilience framework to help growth-stage companies that want to scale without undermining liquidity. Fractional CFO Team Delivers Financial Clarity The framework is designed to help founders and executives understand a common but often misunderstood problem: ...

STZ Player Logo CASABLANCA, Morocco, Feb. 08, 2026 (GLOBE NEWSWIRE) -- STZ Player, a provider of digital entertainment solutions, announces the launch of its media player platform, designed to support modern viewing habits across multiple devices. The platform offers streamlined content access, high-quality playback, and flexible playlist management for entertainment providers, resellers, and end users. At its core, STZ Player delivers a seamless viewing experience optimized for smart TVs, Android devices, ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased securities of PomDoctor Ltd. during the specified Class Period, highlighting potential fraudulent activities affecting the company's stock price [1][5]. Group 1: Class Action Details - The class action lawsuit is for purchasers of PomDoctor securities between October 9, 2025, and December 11, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information via the provided link or contact the law firm directly [3][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements [4]. Group 3: Allegations Against PomDoctor - The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme, which included misinformation on social media and impersonation of financial professionals [5]. - It is claimed that insiders used offshore accounts to facilitate the dumping of shares during a price inflation campaign, and that the company's public statements omitted critical information regarding false rumors and artificial trading activity [5]. - As a result of these actions, the positive statements made by PomDoctor regarding its business and prospects were misleading, leading to investor damages when the truth was revealed [5].

Core Insights - TG Therapeutics, Inc. has launched a new initiative in collaboration with actress Christina Applegate to raise awareness about multiple sclerosis (MS) and facilitate open conversations among those affected by the disease [3][4][7] Group 1: Campaign Overview - The campaign debuted during Super Bowl LX and introduced a new platform, www.NextInMS.com, aimed at creating a space for honest discussions among individuals living with MS [1][3] - Christina Applegate, who has been living with MS for five years, will lead this national disease-awareness initiative [4][5] - The platform will feature exclusive content, including Applegate's personal experiences and insights on navigating life with MS, as well as educational resources from MS experts [5][8] Group 2: Company Commitment - TG Therapeutics emphasizes its commitment to advancing innovation in MS treatment, which includes developing novel therapies and supporting resources for patients [7][9] - The collaboration with Applegate is seen as a way to resonate with the MS community and promote open dialogue about the challenges and realities of living with the disease [6][7]

Core Insights - The claim process is crucial for travel insurance, especially for senior citizens, as it can significantly impact their experience during emergencies abroad [2][9] - Understanding the differences between cashless and reimbursement claims is essential for selecting the right travel insurance plan [3][10] Cashless Claims - Cashless claims allow insurers to settle hospital bills directly with network hospitals, which is beneficial for quick access to care [4][9] - This method requires timely communication with the insurer and adherence to their instructions during hospital admissions [4][11] Reimbursement Claims - Reimbursement claims involve upfront payment by the insured, followed by filing a claim with supporting documents [5][11] - This option is often necessary when treatment occurs at non-network hospitals or when cashless options are unavailable [5][11] Importance for Senior Travelers - Senior travelers benefit from cashless claims for immediate care without financial stress, but they also need flexibility for situations where network hospitals are not available [9][10] - The best approach combines cashless options when possible and reimbursement readiness when necessary [10] Decision-Making Factors - Key questions to consider when choosing travel insurance include upfront payment requirements, hospital choice, speed of claims processing, and paperwork load [11][12] - Cashless claims are preferable for smoother billing at network facilities, while reimbursement offers greater flexibility [11] Documentation and Common Mistakes - To facilitate claims, travelers should keep essential documents organized and avoid common mistakes such as delaying communication with insurers or failing to disclose pre-existing conditions [12][12] - Maintaining a habit of collecting itemized bills and proof of payment is crucial for reimbursement claims [12]